BioSpace News Archive

Catalyst Pharmaceuticals, Inc. today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations.

Mersana Therapeutics, Inc. today announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective Monday, August 16, 2021.

Praxis Precision Medicines, Inc. today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Biosight Ltd . today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Ovid Therapeutics Inc. today reported financial results for the quarter ended June 30, 2021.

Aerovate Therapeutics, Inc. today announced its financial results for the quarter ended June 30, 2021, and recent events.

SCYNEXIS, Inc. today reported financial results for the second quarter ended on June 30, 2021 and provided an update on recent clinical and corporate developments.

HiberCell announced today the acquisition of Genuity Science, Inc., a life science technology company that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases.

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), announced today that the Medicines and Healthcare products Regulatory Agency (MHRA), the pharmaceuticals regulator in the UK, agreed with Galmed’s plan to proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.